Sarepta Therapeutics agreed to pay Regenxbio $39 million to settle gene therapy claims, according to the reported terms. The settlement is framed as resolving a dispute that could otherwise complicate company resources and focus across ongoing AAV gene therapy programs. The payment signals a willingness by both sides to move past litigation rather than extend uncertainty into future trial planning or commercialization strategies. In the gene therapy space, where timelines and regulatory interactions are already resource-intensive, settlements can materially affect operational bandwidth. The news also underlines how legal risk remains a persistent factor alongside clinical and manufacturing execution for AAV-based therapies.